Transeptal Mitral Annuloplasty With the AMEND System: 6-Month Results of First in Man Cohort
Circulation: Cardiovascular Interventions · 2026-06 · 19 (6)
DOI: 10.1161/circinterventions.125.015977 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026-06. Verfasst von Bruno Melica und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Vila Nova de Gaia/Espinho Hospital Center, Portugal (B.M.). Hauptthemen laut MEDLINE: Mitral Valve, Mitral Valve Annuloplasty, Mitral Valve Insufficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The AMEND implant is a semi-rigid closed D-shaped annuloplasty ring deployed through a transvenous transeptal approach. It is aimed to affect selective anteroposterior dimensional reduction, improving leaflet coaptation, and reduce mitral regurgitation (MR). We report the 6-month outcomes of the first cohort treated. METHODS: Thirteen patients with the grade 3 or 4 functional MR were treated in 2 studies in Georgia and Israel, and with compassionate approvals in Portugal and France. They underwent mitral repair with the AMEND annuloplasty and were followed for 6 months. RESULTS: There were no deaths, myocardial infarctions, strokes or cardiac surgery. There were 2 pericardial effusions, 1 acute and the second at 4 months. There was no anchor disengagement or device dehiscence over the follow-up period. There was a single patient who was readmitted with heart failure, and the iatrogenic atrial septal defect was closed. At 6 months the overall anteroposterior dimensional reduction achieved acutely was maintained, with MR reduction being stable, with 11 of 13 patients with ≤grade 1 MR. CONCLUSIONS: In this small multicenter cohort of patients, the AMEND annuloplasty procedure demonstrated promising safety, with stable and significant reduction of MR maintained over the 6-month follow-up period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Vila Nova de Gaia/Espinho Hospital Center, Portugal (B.M.).
- Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Israel (S.C.).
- Lev Leviev Heart Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel (A.B.).
- Healthycore Medical Center, Tbilisi, Georgia (I.G., M.M.). American Hospital Tbilisi, Georgia.
- Department of Cardiology and Cardio-Vascular Surgery, Hôpital Cardiologique de Haut-Lévêque, Bordeaux University Hospital, Pessac, France (T.M.).
- Tbilisi Institute of Medicine, Ilia State University Medical School, Tbilisi Heart and Vascular Clinic, Georgia (L.K.).
ORCID-Profile: Bruno Melica, Shemy Carasso, Irakli Gogorishvili, Thomas Modine, David Meerkin
Zitieren
APA
Melica, B., Carasso, S., Butnaru, A., Gogorishvili, I., Metreveli, M., Modine, T., Kurashvili, L., Farkash, R., & Meerkin, D. (2026). Transeptal Mitral Annuloplasty With the AMEND System: 6-Month Results of First in Man Cohort. Circulation: Cardiovascular Interventions, 19(6). https://doi.org/10.1161/circinterventions.125.015977
Vancouver
Melica B, Carasso S, Butnaru A, Gogorishvili I, Metreveli M, Modine T, et al. Transeptal Mitral Annuloplasty With the AMEND System: 6-Month Results of First in Man Cohort. Circulation: Cardiovascular Interventions. 2026;19(6). doi:10.1161/circinterventions.125.015977
BibTeX
@article{Melica2026,
author = {Melica, Bruno and Carasso, Shemy and Butnaru, Adi and Gogorishvili, Irakli and Metreveli, Mikhael and Modine, Thomas and Kurashvili, Levan and Farkash, Rivka and Meerkin, David},
title = {Transeptal Mitral Annuloplasty With the AMEND System: 6-Month Results of First in Man Cohort},
journal = {Circulation: Cardiovascular Interventions},
year = {2026},
volume = {19},
number = {6},
doi = {10.1161/circinterventions.125.015977}
}
EUVIMED